HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine.

Abstract
Although carcinosarcoma occurs in various locations throughout the body, it rarely originates in the ovary. Chemotherapy has been minimally beneficial. This case describes a patient with carcinosarcoma of the ovary who responded minimally to chemotherapy used for epithelial carcinomas but had a complete response after receiving chemotherapy used for sarcomas. The patient relapsed within 1 year after receiving cisplatin therapy. She was treated with mesna, ifosfamide, Adriamycin, and dacarbazine (MAID) chemotherapy and after one cycle of chemotherapy she had no evidence of tumor. She has received six cycles of chemotherapy without evidence of progression 13+ months since beginning MAID therapy. MAID chemotherapy may be useful in the treatment of carcinosarcoma of the ovary.
AuthorsS R Simon, S E Wang, M Uhl, S Shackney
JournalGynecologic oncology (Gynecol Oncol) Vol. 41 Issue 2 Pg. 161-6 (May 1991) ISSN: 0090-8258 [Print] UNITED STATES
PMID2050307 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Dacarbazine
  • Doxorubicin
  • Ifosfamide
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinosarcoma (drug therapy, pathology, radiography)
  • Combined Modality Therapy
  • Dacarbazine (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Female
  • Humans
  • Ifosfamide (administration & dosage)
  • Middle Aged
  • Ovarian Neoplasms (drug therapy, pathology, radiography)
  • Pelvis (radiography)
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: